AVANOS MEDICAL (AVNS) Company Report

Avanos Medical exceeded its 2025 revenue and EPS guidance and projects mid-single-digit consolidated growth for 2026, with Specialty Nutrition growing mid-to-high single digits and Pain Management low-to-mid single digits.
The company aims to achieve $1 billion in revenue by 2030, supported by solid mid-single-digit organic growth and approximately $100 million in acquisitions over the period.
Avanos is mitigating Section 301 tariffs by relocating syringe production from China to Mexico and Cambodia by June 2026, expecting a tariff benefit in 2027. However, its 2026 EPS guidance incorporates an additional $12 million in tariffs compared to 2025.
Strategically, Avanos is focused on synergistic acquisitions in Specialty Nutrition, such as the successful Nexus Medical acquisition, and has divested underperforming assets. The company is closely monitoring its surgical pain pump business for potential restructuring or divestiture.

6 days ago

Transcript

Avanos Medical outlines 2026 growth and long-term $1 billion revenue target by 2030

AVNS

Guidance Update

M&A

New Projects/Investments

Avanos Medical is confident in its 2026 guidance for mid-single-digit consolidated growth, with mid- to high growth in Specialty Nutrition and low- to mid-single digits in Pain Management.
The company expects earnings expansion in 2026 despite an additional $12 million in tariffs, supported by pricing actions and $15 million-$20 million in incremental annualized savings from a cost reduction program.
Avanos aims to reach $1 billion in revenue by 2030, driven by solid mid-single-digit organic growth and approximately $100 million in total acquisitions over the period, primarily in Specialty Nutrition.
Tariff mitigation efforts are ahead of schedule, with syringe production moving out of China to Mexico and Cambodia by June, reducing the Section 301 tariff burden.
Strategic focus includes the successful integration of Nexus Medical into Neonatal Solutions, which is exceeding plans and serves as a platform for future M&A, while the surgical pain pump business is under close review for potential restructuring or divestiture if performance does not improve.

6 days ago

Transcript

Avanos Medical Discusses 2025 Performance, 2026 Outlook, and Long-Term Strategy

AVNS

Guidance Update

M&A

New Projects/Investments

Avanos Medical exceeded 2025 revenue and EPS guidance and projects mid-single-digit growth for 2026, with mid-to-high growth in Specialty Nutrition and low-to-mid growth in Pain Management.
The company aims for $1 billion in revenue by 2030, supported by mid-single-digit organic growth and approximately $100 million in strategic acquisitions over that period.
Avanos is actively mitigating tariff impacts, expecting to cease syringe production in China by June 2026 and shifting to Mexico and Cambodia. Despite an anticipated $12 million increase in tariffs for 2026, the company forecasts earnings expansion.
Strategic portfolio adjustments include the divestiture of underperforming assets (hyaluronic acid and Game Ready rental business) and the acquisition of Nexus Medical to bolster the Specialty Nutrition segment.
Within Pain Management, RF ablation is experiencing high single-digit to double-digit growth, while the surgical pain pump business is under close review for potential restructuring or divestiture if performance does not improve.

6 days ago

Transcript

Avanos Medical, Inc. to Nominate New Directors and Enters Cooperation Agreement

AVNS

Board Change

Avanos Medical, Inc. announced its intention to nominate James L. Cunniff and William P. Burke as independent directors for election to its Board of Directors at the 2026 Annual Meeting of Stockholders.
This decision follows a cooperation agreement with Bradley L. Radoff and one of his affiliates, which includes the nomination of Mr. Cunniff and another independent director (Mr. Burke).
As part of the agreement, Bradley L. Radoff has withdrawn his previous director nomination and the Radoff Parties have committed to certain standstill restrictions and voting commitments until the 2027 Annual Meeting.
Mr. Cunniff, President and CEO of Electromed, Inc., and Mr. Burke, former EVP and CFO of Haemonetics Corporation, are expected to bring significant operating, finance, and accounting experience to the Board.

Feb 26, 2026, 12:02 PM

8-K

Avanos Medical Announces Q4 and Full Year 2025 Results and 2026 Guidance

AVNS

Earnings

Guidance Update

M&A

Avanos Medical reported full year 2025 net sales of $701 million and adjusted diluted earnings per share of $0.94, exceeding revised guidance, with Q4 2025 net sales at $181 million and adjusted diluted EPS at $0.29.
The company provided 2026 guidance projecting net sales of $700 million to $720 million and adjusted diluted earnings per share of $0.90 to $1.10, driven by anticipated around 5% consolidated organic growth.
Strategic segments delivered strong organic growth in 2025, with Specialty Nutrition Systems growing over 8% and Pain Management & Recovery up 2.3%. The company is also executing a China exit strategy for syringe manufacturing by June 2026, expecting full-year 2026 tariff P&L costs of approximately $30 million, a $12 million increase from 2025.
Key portfolio actions included the divestiture of its hyaluronic acid business, exiting the Game Ready rental business, and the acquisition of Nexus Medical, with the IV therapy business exit scheduled for Q1 2026.

Feb 24, 2026, 2:00 PM

Transcript

AVNS Reports Q4 and Full-Year 2025 Results

AVNS

Earnings

Guidance Update

M&A

AVNS reported FY 2025 revenue of $701 million and adjusted diluted earnings per share of $0.94, exceeding revised estimates.
The company achieved 6% organic growth in strategic segments, with the Specialty Nutrition Systems segment growing 8.2% organically in FY 2025.
Strategic actions included the acquisition of Nexus Medical and the divestiture of the Hyaluronic Acid product line, alongside plans to exit the IV therapy business.
Operational initiatives are expected to deliver $15-$20 million in incremental annualized savings by the end of 2026.
For 2026, AVNS estimates adjusted diluted earnings per share to be between $0.90 and $1.10.

Feb 24, 2026, 2:00 PM

Presentation

Avanos Medical Reports Q4 and Full Year 2025 Results, Provides 2026 Outlook

AVNS

Earnings

Guidance Update

M&A

Avanos Medical reported full year 2025 net sales of $701 million and adjusted diluted earnings per share of $0.94, exceeding its revised guidance. For Q4 2025, net sales were approximately $181 million with adjusted diluted EPS of $0.29.
The company issued 2026 guidance, projecting net sales between $700 million and $720 million and adjusted diluted earnings per share of $0.90 to $1.10.
Avanos expects approximately $30 million in tariff P&L costs for 2026, an increase of $12 million from 2025, but is confident in its plan to be fully exited from China for its syringe portfolio by June 2026.
Key strategic actions in 2025 included the divestiture of the hyaluronic acid business, exiting the Game Ready rental business, and the acquisition of Nexus Medical.

Feb 24, 2026, 2:00 PM

Transcript

Avanos Medical Reports Q4 and Full Year 2025 Results, Provides 2026 Outlook

AVNS

Earnings

Guidance Update

M&A

Avanos Medical reported full-year 2025 net sales of $701 million and adjusted diluted earnings per share of $0.94, exceeding the revised guidance ranges.
The company's strategic segments demonstrated strong organic growth in 2025, with Specialty Nutrition Systems (SNS) growing over 8% and Pain Management & Recovery (PMNR) up 2.3%.
For 2026, Avanos forecasts net sales in the range of $700 million to $720 million and adjusted diluted earnings per share of $0.90 to $1.10, anticipating approximately $30 million in tariff P&L costs.
Strategic initiatives include successful tariff mitigation efforts, with plans to exit all China syringe manufacturing by June 2026, and portfolio shaping through the acquisition of Nexus Medical and divestitures of the hyaluronic acid and IV therapy businesses.

Feb 24, 2026, 2:00 PM

Transcript

Avanos Reports Q4 2025 Results and 2026 Revenue Projections

AVNS

Earnings

Guidance Update

Revenue Acceleration/Inflection

Avanos reported Q4 2025 adjusted EPS of $0.29 and revenue of $180.9 million, exceeding Street estimates and marking its third EPS beat in the last four quarters.
The company projects revenue of $700–$720 million by 2026, attributing cost benefits to exiting China, tariff-mitigation, and expanded transformation initiatives.
Despite top-line momentum, Avanos faces profitability challenges with negative net margins and EPS, and a low Altman Z-Score of -0.13, indicating financial distress risk.
Avanos shares have rallied approximately 35.6% year-to-date, significantly outperforming the S&P 500, while insiders have been net sellers and institutional ownership changes have been mixed.

Feb 24, 2026, 12:14 PM

Morningstar

Avanos Medical, Inc. Announces Fourth Quarter and Full-Year 2025 Results

AVNS

Earnings

Guidance Update

Avanos Medical, Inc. exceeded full-year revenue and achieved the top end of full-year earnings-per-share guidance for 2025, delivering 6% organic growth in strategic segments.
For the fourth quarter of 2025, net sales were $180.9 million and adjusted diluted earnings per share were $0.29.
For the full-year 2025, net sales increased 1.9% to $701.2 million and adjusted diluted earnings per share were $0.94. Full-year adjusted EBITDA totaled $86.8 million and free cash flow was $43.1 million.
The company's net debt as of December 31, 2025, was $10.7 million, compared to $27.0 million in the prior year.
Avanos Medical, Inc. provided 2026 adjusted diluted earnings per share guidance of $0.90 to $1.10.